Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNP-OVA323
- Development stage
- Preclinical
- Lead developer
- Northwestern University
- Modality
- Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CNP-OVA323 is a preclinical antigen-specific immune tolerance candidate developed by Cour Pharmaceuticals in collaboration with Northwestern University. It consists of biodegradable poly(lactide-co-glycolide) (PLGA) nanoparticles encapsulating the OVA323-339 peptide, a CD4+ T-cell epitope derived from chicken ovalbumin. CNP-OVA323 is designed to mimic apoptotic debris, targeting antigen-presenting cells in the liver and spleen to induce immune tolerance. In the RIP-mOVA mouse model of type 1 diabetes, treatment with CNP-OVA323 has been shown to reverse dysglycemia and prevent CD8+ T-cell-mediated autoimmune destruction of beta cells in a regulatory T-cell-dependent manner.
- Other names
- CNP-OVACNP-OVA323-339CNP-OVA-323-339CNP-OVA 323-339COUR nanoparticle-ovalbumin 323-339
02
Targets
MARCOMHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on CNP-OVA323.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNP-OVA323.